Table 3 Clinicopathologic characteristics of included studies (continued)
From: Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis
Study (Year) | Perioperative Morbidity | Perioperative Mortality | Resection | Adjuvant Therapy | Median Survival (months) | 5-year OS | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Sublobar | Standard | Total | Sublobar | Standard | Total | Sublobar | Standard | ||||
Van Rens (2000) [11] | NA | 12 (14.1%) | 32 | 41 | NA | 55.2 | NA | NA | 19% | NA | NA |
Doddoli (2001) [12] | 4 (11%) | 5 (13%) | 12 | 26 | 11 (29%) | 31 | NA | NA | 32% | NA | NA |
Trousse (2007) [13] | 34 (27.2%) | 6 (29.0%) | 43 | 82 | 62 (49.6%) | 34.932 | NA | NA | 34% | NA | NA |
De Leyn (2008) [14] | 16 (44.4%) | 1 (2.8%) | 26 | 10 | 6 (16.7%) | 49.4 | NA | NA | 38.1% | NA | NA |
Riquet (2008) [15] | 66 (28.2%) | 20 (8.6%) | 54 | 180 | 62 (26.5%) | 30 | NA | NA | 32.7% | 36.4% | 34.1% |
Lee (2009) [16] | NA | NA | 35 | 23 | NA | NA | NA | NA | 66% | 59% | 75% |
Voltolini (2010) [17] | 16 (37%) | 3 (7%) | 28 | 15 | 18 (42%) | 32 | 34 | 32 | 34% | 29% | 42% |
Hamaji (2013) [18] | 47 (29.2%) | 0 | 123 | 38 | 14 (8.7%) | 72.9 | NA | NA | 60.8% | NA | NA |
Ishikawa (2014) [19] | NA | 0 | 54 | 39 | 6 (6.5%) | NA | NA | NA | 87.0% | NA | 92.5% |
Xiao (2017) [20] | 3 (5.8%) | 0 | 38 | 14 | 21 (40.4%) | 52 | 60 | 38 | 40.6% | NA | NA |